• 1
    American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 463: cervical cancer in adolescents: screening, evaluation, and management. Obstet Gynecol. 2010; 116:469-472.
  • 2
    Moscicki A-B, Cox JT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010;14:73-80.
  • 3
    ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 109: cervical cytology screening. Obstet Gynecol. 2009;114:1409-1420.
  • 4
    Apgar BS, Kittendorf AL, Bettcher CM, Wong J, Kaufman AJ. Update on ASCCP consensus guidelines for abnormal cervical screening tests and cervical histology. Am Fam Physician. 2009; 80:147-155.
  • 5
    Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, MacKinnon J, Giuliano A. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control. 2009;20:1129-1138.
  • 6
    Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367:489-498.
  • 7
    Zhao C, Kalposi-Novak P, Austin RM. Follow-up findings in young females with high-grade squamous intraepithelial lesion Papanicolaou test results. Arch Pathol Lab Med. 2011;135:361-364.
  • 8
    Clements AE, Raker CA, Cooper AS, Boardman LA. Prevalence and patient characteristics associated with CIN 3 in adolescents [serial online]. Am J Obstet Gynecol. 2011;204:128.e1-128.e7.
  • 9
    Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28.
  • 10
    Markowitz LE, Dunne EF, Saraiya M, et al; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep56(RR-2):1-24, 2007.
  • 11
    Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years—United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:1117-1123.
  • 12
    Zhang S, Thomas J, Thibodeaux J, Bhalodia A, Abreo F. Teenage cervical screening in a high risk American population [serial online]. Cytojournal. 2011;8:9.
  • 13
    Watson M, Saraiya M, Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008;113(10 suppl):2841-2854.
  • 14
    Wright JD, Davila RM, Pinto KR, et al. Cervical dysplasia in adolescents. Obstet Gynecol. 2005;106:115-120.
  • 15
    Patel A, Galaal K, Burnley C, et al. Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study. Br J Cancer. 2012;106:1753-1759.
  • 16
    Msyamboza KP, Dzamalala C, Mdokwe C, et al. Burden of cancer in Malawi; common types, incidence and trends: national population-based cancer registry [serial online]. BMC Res Notes. 2012;5:149.
  • 17
    Andrae B, Kemetli K, Sparen P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100:622-629.
  • 18
    Moscicki AB, Ma Y, Wibbelsman C, et al. Risks for cervical intraepithelial neoplasia-3 among adolescent and young women with abnormal cytology. Obstet Gynecol. 2008;112:1335-1342.
  • 19
    Dunn TS, Bajaj JE, Stamm CA, Beaty B. Management of the minimally abnormal Papanicolaou smear in pregnancy. J Low Genit Tract Dis. 2001;5:133-137.
  • 20
    Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. ASCUS-LSIL Triage Study (ALTS) Group. Am J Obstet Gynecol. 2003; 188:1406-1412.
  • 21
    Solomon D, Schiffman M, Tarone R. Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. ALTS Study Group. J Natl Cancer Inst. 2001;93:293-299.
  • 22
    Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132: 810-819.